Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.

Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous v3.6.0 tag. This signals an update to the page's template or content without changing the trial information.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedEnrollment status updated to 'No longer looking for participants', and new help sections were added (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention / Treatment heading was reformatted to 'Intervention/Treatment', and the revision tag updated from v3.5.5 to v3.6.0.SummaryDifference0.2%

- Check34 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating an administrative update to the study record rather than a substantive change to study details.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, indicating a small update to the study record metadata on ClinicalTrials.gov.SummaryDifference0.0%

- Check70 days agoChange DetectedTaoyuan District, Taiwan, 333 was replaced with Taoyuan, Taiwan, 333 in the Locations section to standardize the city designation for the study site.SummaryDifference0.0%

- Check77 days agoChange DetectedUpdated the page’s footer revision/version indicator from v3.5.2 to v3.5.3.SummaryDifference0.0%

Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.